沃森生物：冻干带状疱疹病毒mRNA疫苗获得《药物临床试验批准通知书》

Core Viewpoint - Watson Bio has received approval from the National Medical Products Administration for clinical trials of a freeze-dried varicella-zoster virus mRNA vaccine, developed in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd [1] Group 1: Company Developments - Watson Bio's subsidiary, Beijing Watson Innovation Biotechnology Co., Ltd., along with Yunnan Vaccine Laboratory Co., Ltd. and Yuxi Watson Biotechnology Co., Ltd., is involved in the joint development of the mRNA vaccine [1] - The clinical trial approval notification number is 2025LP03354; 2025LP03355, and the vaccine is classified as a preventive biological product [1] - The approval indicates that the vaccine meets the requirements for drug registration as per Chinese regulations, allowing for clinical trials aimed at preventing shingles [1] Group 2: Financial Performance - For the first half of 2025, Watson Bio's revenue composition is as follows: self-developed vaccines account for 94.82%, intermediate product revenue 4.67%, other business 0.26%, and service revenue 0.24% [1] - As of the report date, Watson Bio's market capitalization stands at 18.1 billion yuan [1]